- Home
- IDYA vs PSNY Comparison
IDYA vs PSNY Comparison
Compare IDYA & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- PSNY
- Stock Information
- Founded
- IDYA 2015
- PSNY 2017
- Country
- IDYA United States
- PSNY Sweden
- Employees
- IDYA N/A
- PSNY N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- PSNY Auto Manufacturing
- Sector
- IDYA Health Care
- PSNY Consumer Discretionary
- Exchange
- IDYA Nasdaq
- PSNY Nasdaq
- Market Cap
- IDYA 2.3B
- PSNY 1.8B
- IPO Year
- IDYA 2019
- PSNY N/A
- Fundamental
- Price
- IDYA $31.60
- PSNY $0.85
- Analyst Decision
- IDYA Buy
- PSNY Hold
- Analyst Count
- IDYA 17
- PSNY 2
- Target Price
- IDYA $48.20
- PSNY $1.25
- AVG Volume (30 Days)
- IDYA 1.3M
- PSNY 3.3M
- Earning Date
- IDYA 11-04-2025
- PSNY 09-03-2025
- Dividend Yield
- IDYA N/A
- PSNY N/A
- EPS Growth
- IDYA N/A
- PSNY N/A
- EPS
- IDYA N/A
- PSNY N/A
- Revenue
- IDYA $7,000,000.00
- PSNY $2,547,619,000.00
- Revenue This Year
- IDYA $90.17
- PSNY $82.42
- Revenue Next Year
- IDYA $219.42
- PSNY $47.97
- P/E Ratio
- IDYA N/A
- PSNY N/A
- Revenue Growth
- IDYA N/A
- PSNY 24.82
- 52 Week Low
- IDYA $13.45
- PSNY $0.82
- 52 Week High
- IDYA $33.64
- PSNY $1.42
- Technical
- Relative Strength Index (RSI)
- IDYA 63.75
- PSNY 36.81
- Support Level
- IDYA $28.17
- PSNY $0.83
- Resistance Level
- IDYA $33.64
- PSNY $0.90
- Average True Range (ATR)
- IDYA 1.70
- PSNY 0.03
- MACD
- IDYA 0.33
- PSNY 0.00
- Stochastic Oscillator
- IDYA 72.58
- PSNY 17.79
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.